Aclaris Therapeutics, Inc. Other Current Liabilities
Aclaris Therapeutics, Inc. (ACRS) had Other Current Liabilities of $2.79 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Other Liabilities, Current $2.79M.
- 2026-03-31: Other Liabilities, Current $2.77M.
- 2025-12-31: Other Liabilities, Current $2.75M.
- 2025-09-30: Other Liabilities, Current $2.73M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.79M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $2.77M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $2.75M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.72M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $2.70M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $2.68M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $2.67M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $2.65M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $2.71M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $2.63M 10-K · filed 2025-02-27 | |
| 2022-03-31 | $716.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $693.00K 10-Q · filed 2022-05-10 | |
| 2021-09-30 | $669.00K 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $647.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $625.00K 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $603.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $591.00K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $610.00K 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $624.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $637.00K 10-K · filed 2021-02-25 | |
| 2019-09-30 | $642.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $991.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $868.00K 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $142.00K 10-K · filed 2020-02-25 | $601.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |